Analysis of the Influencing Factors of Tumor Volume, Body Immunity, and Poor Prognosis after ¹²⁵I Particle Therapy for Differentiated Thyroid Cancer

Table 5

Univariate analysis of factors influencing the efficacy of ¹²⁵I particle therapy for differentiated TC.

Related factors	Effective group ()	Ineffective group ()
Gender
Male	33 (38.82)	11 (57.89)	2.314	0.128
Female	52 (61.18)	8 (42.11)
Age
<45 years old	47 (55.29)	7 (36.84)	2.118	0.146
≥45 years old	38 (44.71)	12 (63.16)
Pathological type
Papillary adenocarcinoma	51 (60.00)	5 (26.32)	7.090	0.008
Follicular adenocarcinoma	34 (40.00)	14 (73.68)
Tumor size
<2 cm	63 (74.18)	7 (36.84)	9.806	0.002
≥2 cm	22 (25.88)	12 (63.16)
Number of lesions
Single	27 (31.76)	9 (47.38)	1.671	0.196
Multiple	58 (68.24)	10 (52.63)
Invasion
No invasion of capsule	30 (35.29)	5 (26.32)	0.974	0.808
Membrane invasion	27 (31.76)	8 (42.11)
Slight invasion outside the thyroid	16 (18.82)	3 (15.79)
Obvious invasion outside the thyroid	12 (14.12)	3 (15.79)
Clinical stage
I~II stage	60 (70.59)	8 (42.11)	5.566	0.018
III~IV stage	25 (29.41)	11 (57.89)
Distant metastasis
Yes	30 (35.29)	13 (68.42)	7.027	0.008
No	55 (64.71)	6 (31.58)
TSH level before ^125I particle therapy (mIU/L)
<30	1 (1.18)	2 (10.53)	7.896	0.048
30~59	37 (43.53)	4 (21.05)
60~89	24 (28.24)	5 (26.32)
≥90	23 (27.06)	8 (42.11)

Note: TSH: thyroid-stimulating hormone.